3van den Berg H M, Fischer K. Prophylaxis for severe hemophilia: experience from Europe and the United States. Semin Thromb Hemost, 2003, 29:49-54.
4Mannucci P M. Hemophilia: treatment opinions in the twenty-first century. J Thromb Haemost. 2003. 1:1349-1355.
5Boggio L. Inhibitor development with second generation(sucrose formulated) recombinant factor Ⅷ. Biomed Prog, 2003, 16(Suppl 2):4--6.
6Lusher J M, Lee C A, Kessler C M, et al. The safety and efficacy of B-domain deleted recombinant factor Ⅷ concentrate in patients with severe haemophilia, Haemophilia, 2003, 9:38-49.
7Lethagen S. Desmopressin in mild Hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost, 2003, 29 :101 - 106.
8Oranwiroon S, Akkarapatumwong V, Pung-Amritt P,et al. Determination of hemophilia A carrier by mutation analysis. Haemophilia, 2001, 7:20-25.
9VandenDriessehe T, Collen D, Chuah M K L. Gene therapy for the hemophilias. J Thromb Haemost.2003, 1:1550-1558.
10Frachini M. Acquired hemophilia A. Biomed Prog,2003, 16(Suppl3) :1-4.
